Delbart Wendy, Vercruyssen Marie, Danieli Rachele, Marin Clémentine, Wimana Zéna, Meuleman Nathalie, Flamen Patrick, Woff Erwin, Karfis Ioannis
Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Hematology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium, Brussels, Belgium.
EJNMMI Rep. 2025 Jul 28;9(1):26. doi: 10.1186/s41824-025-00262-8.
Radiotheranostics using somatostatin receptor (R)-targeted agents has transformed the management of neuroendocrine tumors, yet its application in other oncological entities remains unexplored. Here, we report the firsSt-inST-human use of [Lu]Lu-DOTATATE in two patients with advanced, triple-class refractory multiple myeloma, selected based on dual imaging with [Ga]Ga-DOTATATE and [F]F-FDG PET/CT. Both patients received standard activities of [Lu]Lu-DOTATATE, resulting in favourable safety profiles and improved quality of life. One patient achieved sustained metabolic response and clinical stability over 12 months, while the second showed a complete metabolic response before experiencing biological progression. Treatment was associated with transient, non-clinically significant myelotoxicity. These findings support the feasibility of Peptide Receptor Radionuclide Therapy (PRRT) in multiple myeloma and suggest potential therapeutic benefit in selected patients. Further clinical investigation is warranted to validate these promising preliminary results.
使用靶向生长抑素受体（R）的药物进行放射治疗诊断已改变了神经内分泌肿瘤的治疗方式，但其在其他肿瘤实体中的应用仍未得到探索。在此，我们报告了首例人体使用[镥]镥-奥曲肽的情况，该药物用于两名晚期、三重难治性多发性骨髓瘤患者，这两名患者是根据[镓]镓-奥曲肽和[氟]氟-脱氧葡萄糖PET/CT双成像选择的。两名患者均接受了标准剂量的[镥]镥-奥曲肽，结果显示安全性良好且生活质量得到改善。一名患者在12个月内实现了持续的代谢反应和临床稳定，而另一名患者在出现生物学进展之前表现出完全的代谢反应。治疗与短暂的、无临床意义的骨髓毒性相关。这些发现支持了肽受体放射性核素治疗（PRRT）在多发性骨髓瘤中的可行性，并提示在选定患者中可能具有治疗益处。有必要进行进一步的临床研究以验证这些有前景的初步结果。
